Get 40% Off
💰 Warren Buffett reveals a $6.72 billion stake in ChubbCopy Portfolios

Merck's CEO to succeed Ken Frazier as chairman

Published 10/26/2022, 05:28 PM
Updated 10/26/2022, 05:31 PM
© Reuters. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/

(Reuters) - Merck & Co said on Wednesday Chief Executive Officer Rob Davis would succeed Chairman Ken Frazier, taking on the additional role effective Dec. 1.

Frazier, who has been a key growth driver of the drugmaker for decades, joined Merck around 30 years ago and became the first Black CEO of a major drug company in 2011.

He has steered the company through the daunting litigation tied to withdrawn painkiller Vioxx, and also played a key role in Merck's 2009 acquisition of U.S. drugmaker Schering-Plough, picking up what would become the company's top-selling drug, Keytruda.

Frazier made headlines in 2017 when he became the first business leader to leave former U.S. President Donald Trump's manufacturing council following Trump's comments on a white nationalist rally held in Charlottesville, Virginia.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.